Pfizer's $2.3 billion civil and criminal penalty over off-label promotions, shows that the federal government is serious about compliance in the health industry
Pfizer’s $2.3 billion civil and criminal penalty over off-label promotions, shows that the federal government is serious about compliance in the health industry, say experts.
The overall settlement is the largest ever paid by a drug company for alleged violations of federal drug rules.
“Consider that reducing fraud, abuse and waste in healthcare will save the health system-including government and taxpayers-billions and prosecuting fraud, abuse and waste collects billions for the government. That’s a double ‘win’ for taxpayers, so it’s popular with all politicians,” says Kathy Roe, a partner in the Health Law Consultancy in Chicago.
Jack Rovner, who is also a partner, advises executives to take compliance seriously.
“Real compliance takes time, investment of resources, and the absolute commitment of the most senior management to values,” Rovner says. “To find the evidence of a company’s commitment to compliance, look in the budget. For example, it would be informative to compare Pfizer’s investment in marketing versus its investment in compliance.”
Both Roe and Rovner agree that compliance is not just about following the law; it’s about doing the right thing.
“Sports like football have rules, but sportsmanship is much more than merely following those rules,” Roe explains.
There is ever-increasing danger in pushing against the “gray” inherent in any set of rules to increase sales with ethically-if not legally- doubtful tactics, according to Rovner.
“Both whistleblowers and government prosecutors have 2.3 billion reasons to keep a sharp-eye on pharma and, indeed, on all health industry participants,” he says.
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Listen
In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.
Listen
A Motor Neuron Mystery Points to New Potential SMA Treatment Targets
December 20th 2024Some muscles are resistant to the loss of motor neurons seen in patients with spinal muscular atrophy, and new research has discovered that even in muscles that appeared resistant to SMA, subtle changes had occurred at the cellular level.
Read More